Total Revenue (2024): $560 million, representing 29% growth over 2023. Crysvita Revenue (2024): $410 million, with 25% growth over 2023. Dojolvi Revenue (2024): $88 million, representing 25% growth over 2023. Evkeeza Revenue (2024): $32 million. Mepsevii Revenue (2024): $30 million. Total Operating Expenses (2024): $1.1 billion. R&D Expenses (2024): $698 million. SG&A Expenses (2024): $322